Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:IMR) ).
Imricor Medical Systems has announced that Charité University Hospital in Berlin, one of the world’s leading hospitals, will become the second site globally to join the company’s VISABL-VT clinical trial, which is aimed at advancing real-time MRI-guided ablation for ventricular tachycardia. Following software upgrades to Charité’s Philips MRI system to integrate Imricor’s NorthStar mapping platform and the removal of now-commercial CE-marked Imricor devices from the investigational study framework, the trial protocol has been simplified, and Charité’s electrophysiology team plans to begin commercial atrial flutter ablations in the MRI lab from the first quarter of 2026, underscoring Imricor’s strengthening clinical footprint and its strategic collaboration with Philips in MRI-guided electrophysiology.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
More about Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
Imricor Medical Systems, Inc. is a medical technology company focused on enabling interventional cardiac procedures to be performed under real-time magnetic resonance imaging (MRI) guidance instead of traditional x-ray fluoroscopy, leveraging MRI’s superior imaging capabilities. The company is a pioneer in MRI-compatible products for cardiac catheter ablation, offering capital equipment such as the NorthStar Mapping System and Advantage-MR EP Recorder/Stimulator, as well as single-use ablation and diagnostic catheters and steerable sheaths, with approvals in the EU, Saudi Arabia and New Zealand and further regulatory clearances, including in the US and Australia, in progress.
Average Trading Volume: 241,174
Technical Sentiment Signal: Buy
Current Market Cap: A$461.4M
See more data about IMR stock on TipRanks’ Stock Analysis page.